Targeted News Service

ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Achieved Statistically Significant Overall Survival, Reducing The Risk Of Death By 36% Vs. Trastuzumab Emtansine (T-DM1) In Patients With HER2-Positive Metastatic Breast Cancer In DESTINY-Breast03
December 08, 2022

WILMINGTON, Delaware, Dec. 8 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Dec. 7, 2022:

Updated results from the DESTINY-Breast03 Phase III trial showed that ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treat . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form